drugset / Trial / NCT00373113

A Clinical Trial Comparing Efficacy And Safety Of Sunitinib And Capecitabine

NCT00373113

Phase 3 Terminated 482 enrolled Pfizer
RandomizedParallel-groupOpen-labelTreatment

Summary

To compare efficacy and safety of Sunitinib and Capecitabine in subjects with advanced breast cancer who failed both a taxane and an anthracycline chemotherapy regimen or failed with a taxane and for whom further anthracycline therapy is not indicated

Timeline

Start
2006-11
Primary completion
2009-10
Completion
2011-06

Drugs

EvaluationDrugModalityDoseRoute
Comparator Capecitabine Small molecule 1250 mg/m2
Subject Sunitinib Small molecule 37.5 mg

Indications